GSK Acquires Cancer Drug Developer Nuvalent for $10.6 Billion
GSK announced the acquisition of Boston-based biotech company Nuvalent for $10.6 billion in an all-cash deal, paying $124 per share. The purchase represents GSK's largest acquisition in years and reflects the pharmaceutical industry's focus on expanding oncology pipelines as major drugs face generic competition. The deal underscores the growing market importance of cancer treatments as the disease becomes more prevalent and treatable.
GSK, the British pharmaceutical company, has agreed to acquire Nuvalent, a cancer-focused biotech firm based in Boston/Cambridge, Massachusetts, for $10.6 billion in cash. The deal, announced by GSK's new CEO Luke Miels, involves paying $124 per share, representing a 26% premium to Nuvalent's 30-day average share price. Nuvalent specializes in targeted cancer drugs, including late-stage lung cancer treatments such as zidesamtinib and neladalkib. The acquisition is part of a broader industry trend of large pharmaceutical companies bolstering their oncology portfolios to address looming generic competition for key products. The deal reflects the pharmaceutical sector's strategic focus on cancer treatments, driven by both increased disease prevalence due to aging populations and improved survival rates from advances in immunotherapies and targeted treatments.
What different sources said
- SemaforCenter
GSK buys cancer drugmaker Nuvalent for $10B
- STAT NewsCenter
STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
- The Guardian USLeft
GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm
Related
U.S. Markets Stage Rebounds Following Chip Stock Selloff
U.S. markets have rebounded twice following a dramatic Friday selloff in chip stocks, with gains at Monday's open and Tuesday afternoon. The Nasdaq 100 remains down 4.25% for the month despite the recoveries, and volatility has increased sharply. The pattern reflects the market's traditional 'buy the dip' behavior as investors resist giving up recent gains.
Japan's 30-Year Bond Auction Sees Weakest Demand in Over a Year
Japan's 30-year government bond auction on June 10, 2026 attracted the weakest demand since June 2025, with a bid-to-cover ratio of 2.94 compared to the previous 3.49. The decline reflects investor concerns over inflation and fiscal policy, as well as falling yields reducing appetite for the bonds. Weak bond demand can signal investor anxiety about Japan's economic outlook and fiscal sustainability.
HKEx CEO Bonnie Chan Calls Potential SpaceX Listing an 'Exciting Deal'
Hong Kong Exchanges and Clearing (HKEx) CEO Bonnie Chan expressed enthusiasm about a potential SpaceX listing, describing it as an exciting opportunity. Chan highlighted that Chinese supply chains have broad coverage relevant to such a deal. The statement suggests HKEx's interest in attracting major space industry companies to its exchange.